These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 35279641

  • 1. Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy.
    Assaf W, Andraous M, Lavie O, Segev Y.
    Eur J Obstet Gynecol Reprod Biol; 2022 May; 272():48-54. PubMed ID: 35279641
    [Abstract] [Full Text] [Related]

  • 2. Ovarian cancer incidence and death in average-risk women undergoing bilateral salpingo-oophorectomy at benign hysterectomy.
    Cusimano MC, Ferguson SE, Moineddin R, Chiu M, Aktar S, Liu N, Baxter NN.
    Am J Obstet Gynecol; 2022 Feb; 226(2):220.e1-220.e26. PubMed ID: 34563499
    [Abstract] [Full Text] [Related]

  • 3. Risk-reducing Bilateral Salpingo-oophorectomy: Assessing the Incidence of Occult Ovarian Cancer and Surgeon Adherence to Recommended Practices.
    Newcomb LK, Toal CT, Rindos NB, Wang L, Mansuria SM.
    J Minim Invasive Gynecol; 2020 Feb; 27(7):1511-1515. PubMed ID: 31927044
    [Abstract] [Full Text] [Related]

  • 4. Adherence to risk-reducing salpingo-oophorectomy guidelines among gynecologic oncologists compared to general gynecologists.
    Blustein P, Werner SR, Uppalapati P, Leung TM, Husk GA, Pereira EB, Whyte JS, Villella JA.
    Am J Obstet Gynecol; 2023 Sep; 229(3):280.e1-280.e8. PubMed ID: 37308046
    [Abstract] [Full Text] [Related]

  • 5. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS.
    Oncologist; 1996 Sep; 1(5):326-330. PubMed ID: 10388011
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bilateral salpingo-oophorectomy at the time of benign hysterectomy among females with disabilities: a population-based cross-sectional study.
    Scime NV, Brown HK, Metcalfe A, Simpson AN, Brennand EA.
    Am J Obstet Gynecol; 2023 Dec; 229(6):658.e1-658.e17. PubMed ID: 37544349
    [Abstract] [Full Text] [Related]

  • 8. Breast cancer risk after hysterectomy with and without salpingo-oophorectomy for benign indications.
    Chow S, Raine-Bennett T, Samant ND, Postlethwaite DA, Holzapfel M.
    Am J Obstet Gynecol; 2020 Dec; 223(6):900.e1-900.e7. PubMed ID: 32585221
    [Abstract] [Full Text] [Related]

  • 9. Attitudes and clinical practice of Italian gynecologists towards prophylactic oophorectomy during hysterectomy for benign conditions.
    Mezzopane R, Ricci E, Chatenoud L, Cisternino A, Chiantera A, Parazzini F.
    Maturitas; 1996 Jul; 24(3):157-9. PubMed ID: 8844629
    [Abstract] [Full Text] [Related]

  • 10. Hysterectomy with and without oophorectomy and all-cause and cause-specific mortality.
    Tuesley KM, Protani MM, Webb PM, Dixon-Suen SC, Wilson LF, Stewart LM, Jordan SJ.
    Am J Obstet Gynecol; 2020 Nov; 223(5):723.e1-723.e16. PubMed ID: 32376318
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. ACOG Committee Opinion No. 774 Summary: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention.
    Obstet Gynecol; 2019 Apr; 133(4):842-843. PubMed ID: 30913193
    [Abstract] [Full Text] [Related]

  • 14. Management Strategies for the Ovaries at the Time of Hysterectomy for Benign Disease.
    Matthews CA.
    Obstet Gynecol Clin North Am; 2016 Sep; 43(3):539-49. PubMed ID: 27521883
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A Revised Markov Model Evaluating Oophorectomy at the Time of Hysterectomy for Benign Indication: Age 65 Years Revisited.
    Rush SK, Ma X, Newton MA, Rose SL.
    Obstet Gynecol; 2022 May 01; 139(5):735-744. PubMed ID: 35576331
    [Abstract] [Full Text] [Related]

  • 17. Determinants of the decision to perform prophylactic oophorectomy in association with a hysterectomy for a benign condition.
    Plusquin C, Fastrez M, Vandromme J, Rozenberg S.
    Maturitas; 2012 Oct 01; 73(2):164-6. PubMed ID: 22964073
    [Abstract] [Full Text] [Related]

  • 18. Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.
    Perri T, Farhadian Y, Friedman E, Korach J.
    Menopause; 2020 Jan 01; 27(1):82-87. PubMed ID: 31688415
    [Abstract] [Full Text] [Related]

  • 19. Short- and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer.
    Carr CE, Chambers L, Jernigan AM, Freeman L, Escobar PF, Michener CM.
    Int J Gynecol Cancer; 2021 Feb 01; 31(2):215-221. PubMed ID: 32948638
    [Abstract] [Full Text] [Related]

  • 20. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
    Perri T, Levin G, Naor-Revel S, Eliassi-Revivo P, Lifshitz D, Friedman E, Korach J.
    Int J Gynaecol Obstet; 2022 May 01; 157(2):431-436. PubMed ID: 34324701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.